Pendulum Therapeutics Revenue, Valuation, Funding & Investors

Medy-Tox Inc. is a Korea-based company engaged in the development, manufacture, and marketing of biopharmaceuticals. The company's main product is type-A botulium toxin biopharmaceuticals which are used as remedies for blepharospasms, hemifacial spasms, eye wrinkles, hyperhidrosis diseases and infantile cerebral palsy. The group provides its products under the brand names of Neuronox, Siax and others. It distributes its products within Korean and to overseas markets, such as Japan, China, Russia and Europe, among others.

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Cuorips Inc is engaged in the Research, development, manufacturing, and sales of Cellular and Tissue-based Products and Cell processing products. The company is also engaged in Contract development and manufacturing services and consulting services of Cellular and Tissue-based Products and Cell processing product.

AprilBio Co Ltd is a bio company is developing biologis. It owns long acting protein medicine platform technology utilizing human FAB antobody parts that makes unusual combination to serum akbumin and EX 12 helper phase antibody library technology.

Triveni Bio is a Boston-based biotechnology firm developing precision antibody therapies for immunological and inflammatory disorders. The company employs a genetics-driven platform to identify novel targets and accelerate proof-of-concept in early drug development stages. Triveni Bio targets autoimmune diseases like inflammatory bowel disease and rheumatoid arthritis with its proprietary discovery engine.

Animalcare Group PLC is active in the healthcare division in the United Kingdom. It is a generic veterinary medicines company. The company mainly caters to veterinary professionals in the treatment of companion animals through a product line comprised of licensed veterinary medicines and companion animal identification products and services. Its only reportable segment is Pharmaceutical which includes the development and marketing of pharmaceutical products. The company has a presence in Belgium, The Netherlands, Germany, Italy, Portugal, the European Union - Other, Asia, Middle East Africa, Spain, the United Kingdom, and Other Countries of which Spain derives the majority of the revenue to the company.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Readline is a Shenzhen-headquartered biopharmaceutical firm pioneering enzyme-directed evolution for green manufacturing of active pharmaceutical ingredients. Specializing in peptides, carbohydrates, and nucleic acids, it supplies intermediates for medicines, cosmetics, animal feed, and biological pesticides, emphasizing sustainable production processes at industrial scale.

Inceptive is a biotechnology firm that engineers RNA molecules through deep learning models refined by high-throughput wet-lab experiments. Headquartered in South San Francisco, the company builds platforms for designing mRNA vaccines, gene therapies, and protein therapeutics. Its Evo 2.0 model generates novel RNA sequences with specified properties, accelerating development of treatments for infectious diseases and rare genetic disorders.

Valo Health is a Boston-headquartered biotech firm that integrates multimodal human data into its Opal Computational Platform for drug discovery. The platform analyzes real-world evidence, clinical, and molecular datasets to advance therapies in cardiovascular, metabolic, renal, oncology, and neurodegenerative areas. Valo maintains offices in Lexington and New York City alongside its Boston base. Launched in 2018 by Flagship Pioneering, it collaborates with AstraZeneca on heart failure programs and Bayer on cardiovascular targets. The company processes petabytes of data to nominate drug candidates and optimize trials.

Lavipharm SA develops, manufactures, markets, and distributes pharmaceutical, cosmetic, and consumer health products in Greece and internationally. The company's product portfolio includes safe and effective therapeutic solutions that meet consumers' needs for health and well-being. Its main product categories are Cardiology, Oncology, Urology, Neurology, Psychiatry, General Medicine, Self-Treatment, and Dermocosmetic care. Its operating segments include Medicines, Parapharmaceuticals, and Services.